Bioheart, Inc. (OTCPK:BHRT) announces a share repurchase program. Under the program, the company will repurchase its outstanding common stock. Repurchases will be made from time to time through open market transactions, privately negotiated transactions or otherwise, as determined by the company's management depending upon market conditions and business needs in compliance with federal securities laws. The repurchases will be made when beneficially prudent for the company and its shareholders. The share program does not obligate the company to purchase any particular amount of common shares. The program may be suspended, discontinued or modified at any time at the company's discretion and without prior notice.
On October 12, 2015, the company announced a reverse stock split of 1:1,000.
U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector. Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.
U.S. STEM CELL, INC. 
